learn Verteporfin
chemical that might completely regrow follicles from hair transplant extractions
Search
forLearn
5 / 801 resultslearn retinoic acid
learn calcium ascorbate
learn retinol
learn TeraCeutic™
Research
5 / 1000+ resultsresearch 41261 Identification of Demographic and Clinical Features Associated with Multi-Biologic Failure in the CorEvitas Psoriasis Registry
Certain factors like being female, having high cholesterol, using Medicaid, and previous non-biologic treatments increase the risk of multiple biologic failures in psoriasis patients.
research Chinese SLE Treatment and Research group (CSTAR) registry 2009–2019: Major clinical characteristics of Chinese patients with systemic lupus erythematosus
Chinese patients with systemic lupus erythematosus commonly experience oral ulcers, arthritis, alopecia, skin rash, and nephritis.
research COVID-19 clinical outcomes and nationality: results from a Nationwide registry in Kuwait
Non-Kuwaiti COVID-19 patients had worse health outcomes than Kuwaitis, likely due to poorer socioeconomic conditions.
research Clinical and sociodemographic features of alopecia areata in five Colombian cities: an analysis of the RENAAC registry
Most alopecia areata patients in the study were women, aged 15-49, with patchy hair loss and often had other health conditions.
research COVID-19 Clinical Outcomes and Nationality: Results from a Nationwide Registry in Kuwait
Non-Kuwaitis with COVID-19 had higher chances of severe outcomes than Kuwaitis.
Community Join
5 / 1000+ resultscommunity Hope Medicine announces HMI-115 phase II clinical trial for androgenetic alopecia in China
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
community Hold up... CosmeRNA/SAMiRNA is actually coming real soon?
A user discovered CosmeRNA, a new hair loss treatment with clinical research backing, set to release soon. The conversation revolves around its potential effectiveness, cost, and how it compares to existing treatments like Minoxidil and Finasteride, with some users expressing hope for a side-effect-free option.
community Wasn’t hmi-115 phase 1 supposed to end in july? We’ve heard nothing so far
The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.
community Who said GT20029 would be applied only few times per month?
The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
community About GT20029's Efficacy and Strength
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.